Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$39M | — | — | -$17M | — | $3M |
| 2024 | — | $42M | — | — | — | — | $13000 |
| 2022 | — | -$53M | — | — | -$36M | — | $10M |
| 2021 | — | $8M | — | — | — | — | $497412 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$12M | — | — | — | — | $6M |
| Dec '25 | — | -$37M | — | — | -$5M | — | $3M |
| Sep '25 | — | -$5M | — | — | -$3M | — | $6M |
| Jun '25 | — | -$7M | — | — | -$2M | — | $8M |
| Mar '25 | — | $9M | — | — | -$8M | — | $10M |
| Dec '24 | — | $2M | — | — | — | — | $13000 |
| Sep '24 | — | -$6M | — | — | — | — | $537000 |
| Jun '24 | — | $164M | — | — | — | — | $3M |
| Mar '24 | — | -$118M | — | — | — | — | $2M |
| Dec '23 | — | -$26M | — | — | — | — | $5M |
| Sep '23 | — | -$298M | — | — | — | — | $16M |
| Jun '23 | — | -$15M | — | — | — | — | — |
| Mar '23 | — | -$18M | — | — | — | — | — |
| Dec '22 | — | -$35M | — | — | -$8M | — | $10M |
| Sep '22 | — | -$10M | — | — | — | — | $27759 |
| Jun '22 | — | $2M | — | — | — | — | $7758 |
| Mar '22 | — | $3M | — | — | — | — | $166243 |
| Dec '21 | — | $247874 | — | — | — | — | $497412 |
| Sep '21 | — | $6M | — | — | — | — | $663540 |
| Jun '21 | — | -$4M | — | — | — | — | $988855 |
See the revenue and net-income charts above for AEON Biopharma, Inc.'s multi-year trend.
As of FY2025, AEON Biopharma, Inc. reported — of total debt against $3M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.